Tag Archives: BristolMyers

Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb's kidney cancer share

Bristol-Myers Squibb investors have been dreading positive kidney cancer results from archrival Merck for months. And now that they’re here, they might do even more damage to Bristol-Myers’ market share than some industry watchers expected. Results released late Monday in an abstract show that Merck’s immuno-oncology star Keytruda, in tandem with Pfizer’s Inlya, slashed the risk… Read More »

Bristol-Myers yanked its Celgene bid days before deadline—and got a better price

On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to acquire Celgene. But it turns out that wasn’t the case. It ended up scoring a better deal instead. Just days before a Jan. 2 deadline Bristol-Myers itself had set for wrapping up an agreement, the New Jersey drugmaker pulled that proposal—$ 57… Read More »

JPM 2019: Bristol-Myers, Celgene CEOs trot out detailed case for $74B megadeal

SAN FRANCISCO—Bristol-Myers Squibb and Celgene sent 2019’s first big shockwave throughout pharma with last week’s $ 74 billion megamerger announcement. And they immediately touched off questions about the deal: Analysts called it too expensive, not to mention risky on the patent side and pipeline, too. But even as market watchers continued to offer up their reservations on… Read More »